A comparison of the haemostatic effect of Vivostat® patient-derived fibrin sealant with oxidised cellulose (Surgicel®) in multiple surgical procedures

Aim:To evaluate the haemostatic properties of Vivostat(R) patient-derived fibrin sealant in a broad range of surgical procedures. Method. In a prospective, randomised, multicentre, clinical study, typical surgical wounds of 69 patients (cardiothoracic, general, obstetric and gynaecologic, and vascular), requiring intervention to control bleeding, were treated with either Vivostat-derived sealant (n = 35) or Surgicel(R) (n = 34) as required and the time taken to arrest bleeding was assessed. Results: Compared with Surgicel, the mean time to haemostasis of Vivostat-derived sealant was significantly shorter (1.6 vs. 3.3 min, p < 0.0001) and more patients were successfully treated (i.e. no additional haemostatic measures required; 94 vs. 65%, p = 0.003). Conclusion: Vivostat-derived sealant is a more reliable and rapidly effective surgical haemostat than Surgicel. Copyright (C) 2003 S. Karger AG, Basel.